In vivo characterization of interleukin‐4 as a potential wound healing agent

Ahmet Kucukcelebi, Richard H C Harries, Patrick J. Hennessey, Linda Phillips, Lyle D. Broemeling, Dmitry Listengarten, Francis Ko, Satwant Narula, Martin C. Robson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Interleukin‐4 increases the synthesis of extracellular matrix proteins, including types I and III collagen and fibronectin, by both human and rat fibroblasts. Because fibroblasts are the final common effector cells of most phases of tissue repair, this study set out to investigate the effects of interleukin‐4 on the healing of three different types of wounds. Acute excisional and chronic granulating wounds inoculated with Escherichia coli and incisional wounds in streptozotocin‐induced diabetic Sprague‐Dawley rats were used. Recombinant murine or human interleukin‐4 was applied topically to the open wounds at doses of 0.1, 1.0, or 10.0 µg/cm2/wound for 5 or 10 days. Incisional wounds received the same doses once—at the time of wounding. The time taken to achieve wound closure or wound breaking strength measurements of wounds was recorded and compared with relevant untreated control groups. Wound contraction was impaired in the presence of bacteria, and this was reversed by all doses of recombinant murine interleukin‐4. Recombinant murine interleukin‐4 had no effect on the wound closure of noncontaminated wounds; it reduced wound breaking strength in acute excisional wounds, except in a contaminated setting when wounds were treated with 1.0 pg/cm2/wound. Recombinant interleukin‐4 (1.0 µg) improved breaking strength of both diabetic and normal incisional wounds. The apparent pleiotropic effect of interleukin‐4 on wound breaking strength under different wound conditions may be related not only to the activity of the fibroblast but also the ratio of cross‐linked collagen/total collagen content of wounds. This study suggests that interleukin‐4 may be a useful agent for accelerating closure of wounds, particularly where healing is impaired.

Original languageEnglish (US)
Pages (from-to)49-58
Number of pages10
JournalWound Repair and Regeneration
Volume3
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Wound Healing
Wounds and Injuries
Fibroblasts
Collagen
Collagen Type III
Extracellular Matrix Proteins
Collagen Type I
Fibronectins

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Kucukcelebi, A., Harries, R. H. C., Hennessey, P. J., Phillips, L., Broemeling, L. D., Listengarten, D., ... Robson, M. C. (1995). In vivo characterization of interleukin‐4 as a potential wound healing agent. Wound Repair and Regeneration, 3(1), 49-58. https://doi.org/10.1046/j.1524-475X.1995.30110.x

In vivo characterization of interleukin‐4 as a potential wound healing agent. / Kucukcelebi, Ahmet; Harries, Richard H C; Hennessey, Patrick J.; Phillips, Linda; Broemeling, Lyle D.; Listengarten, Dmitry; Ko, Francis; Narula, Satwant; Robson, Martin C.

In: Wound Repair and Regeneration, Vol. 3, No. 1, 1995, p. 49-58.

Research output: Contribution to journalArticle

Kucukcelebi, A, Harries, RHC, Hennessey, PJ, Phillips, L, Broemeling, LD, Listengarten, D, Ko, F, Narula, S & Robson, MC 1995, 'In vivo characterization of interleukin‐4 as a potential wound healing agent', Wound Repair and Regeneration, vol. 3, no. 1, pp. 49-58. https://doi.org/10.1046/j.1524-475X.1995.30110.x
Kucukcelebi, Ahmet ; Harries, Richard H C ; Hennessey, Patrick J. ; Phillips, Linda ; Broemeling, Lyle D. ; Listengarten, Dmitry ; Ko, Francis ; Narula, Satwant ; Robson, Martin C. / In vivo characterization of interleukin‐4 as a potential wound healing agent. In: Wound Repair and Regeneration. 1995 ; Vol. 3, No. 1. pp. 49-58.
@article{a2dcdbe2a1f24fcfa457fbb2791fd494,
title = "In vivo characterization of interleukin‐4 as a potential wound healing agent",
abstract = "Interleukin‐4 increases the synthesis of extracellular matrix proteins, including types I and III collagen and fibronectin, by both human and rat fibroblasts. Because fibroblasts are the final common effector cells of most phases of tissue repair, this study set out to investigate the effects of interleukin‐4 on the healing of three different types of wounds. Acute excisional and chronic granulating wounds inoculated with Escherichia coli and incisional wounds in streptozotocin‐induced diabetic Sprague‐Dawley rats were used. Recombinant murine or human interleukin‐4 was applied topically to the open wounds at doses of 0.1, 1.0, or 10.0 µg/cm2/wound for 5 or 10 days. Incisional wounds received the same doses once—at the time of wounding. The time taken to achieve wound closure or wound breaking strength measurements of wounds was recorded and compared with relevant untreated control groups. Wound contraction was impaired in the presence of bacteria, and this was reversed by all doses of recombinant murine interleukin‐4. Recombinant murine interleukin‐4 had no effect on the wound closure of noncontaminated wounds; it reduced wound breaking strength in acute excisional wounds, except in a contaminated setting when wounds were treated with 1.0 pg/cm2/wound. Recombinant interleukin‐4 (1.0 µg) improved breaking strength of both diabetic and normal incisional wounds. The apparent pleiotropic effect of interleukin‐4 on wound breaking strength under different wound conditions may be related not only to the activity of the fibroblast but also the ratio of cross‐linked collagen/total collagen content of wounds. This study suggests that interleukin‐4 may be a useful agent for accelerating closure of wounds, particularly where healing is impaired.",
author = "Ahmet Kucukcelebi and Harries, {Richard H C} and Hennessey, {Patrick J.} and Linda Phillips and Broemeling, {Lyle D.} and Dmitry Listengarten and Francis Ko and Satwant Narula and Robson, {Martin C.}",
year = "1995",
doi = "10.1046/j.1524-475X.1995.30110.x",
language = "English (US)",
volume = "3",
pages = "49--58",
journal = "Wound Repair and Regeneration",
issn = "1067-1927",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - In vivo characterization of interleukin‐4 as a potential wound healing agent

AU - Kucukcelebi, Ahmet

AU - Harries, Richard H C

AU - Hennessey, Patrick J.

AU - Phillips, Linda

AU - Broemeling, Lyle D.

AU - Listengarten, Dmitry

AU - Ko, Francis

AU - Narula, Satwant

AU - Robson, Martin C.

PY - 1995

Y1 - 1995

N2 - Interleukin‐4 increases the synthesis of extracellular matrix proteins, including types I and III collagen and fibronectin, by both human and rat fibroblasts. Because fibroblasts are the final common effector cells of most phases of tissue repair, this study set out to investigate the effects of interleukin‐4 on the healing of three different types of wounds. Acute excisional and chronic granulating wounds inoculated with Escherichia coli and incisional wounds in streptozotocin‐induced diabetic Sprague‐Dawley rats were used. Recombinant murine or human interleukin‐4 was applied topically to the open wounds at doses of 0.1, 1.0, or 10.0 µg/cm2/wound for 5 or 10 days. Incisional wounds received the same doses once—at the time of wounding. The time taken to achieve wound closure or wound breaking strength measurements of wounds was recorded and compared with relevant untreated control groups. Wound contraction was impaired in the presence of bacteria, and this was reversed by all doses of recombinant murine interleukin‐4. Recombinant murine interleukin‐4 had no effect on the wound closure of noncontaminated wounds; it reduced wound breaking strength in acute excisional wounds, except in a contaminated setting when wounds were treated with 1.0 pg/cm2/wound. Recombinant interleukin‐4 (1.0 µg) improved breaking strength of both diabetic and normal incisional wounds. The apparent pleiotropic effect of interleukin‐4 on wound breaking strength under different wound conditions may be related not only to the activity of the fibroblast but also the ratio of cross‐linked collagen/total collagen content of wounds. This study suggests that interleukin‐4 may be a useful agent for accelerating closure of wounds, particularly where healing is impaired.

AB - Interleukin‐4 increases the synthesis of extracellular matrix proteins, including types I and III collagen and fibronectin, by both human and rat fibroblasts. Because fibroblasts are the final common effector cells of most phases of tissue repair, this study set out to investigate the effects of interleukin‐4 on the healing of three different types of wounds. Acute excisional and chronic granulating wounds inoculated with Escherichia coli and incisional wounds in streptozotocin‐induced diabetic Sprague‐Dawley rats were used. Recombinant murine or human interleukin‐4 was applied topically to the open wounds at doses of 0.1, 1.0, or 10.0 µg/cm2/wound for 5 or 10 days. Incisional wounds received the same doses once—at the time of wounding. The time taken to achieve wound closure or wound breaking strength measurements of wounds was recorded and compared with relevant untreated control groups. Wound contraction was impaired in the presence of bacteria, and this was reversed by all doses of recombinant murine interleukin‐4. Recombinant murine interleukin‐4 had no effect on the wound closure of noncontaminated wounds; it reduced wound breaking strength in acute excisional wounds, except in a contaminated setting when wounds were treated with 1.0 pg/cm2/wound. Recombinant interleukin‐4 (1.0 µg) improved breaking strength of both diabetic and normal incisional wounds. The apparent pleiotropic effect of interleukin‐4 on wound breaking strength under different wound conditions may be related not only to the activity of the fibroblast but also the ratio of cross‐linked collagen/total collagen content of wounds. This study suggests that interleukin‐4 may be a useful agent for accelerating closure of wounds, particularly where healing is impaired.

UR - http://www.scopus.com/inward/record.url?scp=84989026663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989026663&partnerID=8YFLogxK

U2 - 10.1046/j.1524-475X.1995.30110.x

DO - 10.1046/j.1524-475X.1995.30110.x

M3 - Article

VL - 3

SP - 49

EP - 58

JO - Wound Repair and Regeneration

JF - Wound Repair and Regeneration

SN - 1067-1927

IS - 1

ER -